AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know

Core Insights - Amarin's shares have increased by 37.7% over the past year, significantly outperforming the industry's growth of 14.7%, driven by restructuring efforts, cost controls, and optimism regarding international expansion [1][7] Operational Restructuring & Cost Optimization - Amarin's revenue primarily comes from its drug Vascepa/Vazkepa and licensing agreements, with the drug available in over 20 countries. However, U.S. sales are pressured by generic competition [2] - To counteract competition, Amarin has implemented significant operational streamlining and cost reduction measures [2] - A global restructuring program was introduced in June 2025, aiming for $70 million in annual savings, which has positively impacted investor sentiment by extending the company's cash runway and reducing cash burn [3][7] International Growth of AMRN's Vascepa - Amarin is focusing on expanding Vascepa in international markets, particularly in Europe, where it is gaining market access and reimbursement approvals [4] - In June 2025, Amarin signed a long-term license and supply agreement with Recordati to commercialize Vazkepa in 59 European countries [5][7] - The company has established partnerships with seven regional partners, providing access to nearly 100 markets, which is expected to enhance international sales and offset declining U.S. revenues [8] Balance Sheet Strength - The restructuring initiatives have improved Amarin's balance sheet, maintaining a solid cash position and remaining debt-free throughout 2025, which reduces financial risk [9] - The company achieved positive cash flow in Q4 2025, ahead of its previous expectations for 2026 [9]